Dendrimer based nanoarchitectures in diabetes management: An overview by Mishra, Vijay et al.
 1 
 
Dendrimer based nanoarchitectures in diabetes management: An overview 
Vijay Mishra
1
, Nishika Yadav
1
, Gaurav K Saraogi
2
, Murtaza M. Tambuwala
3
, Namita Giri
4* 
 
1
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab) 
2
School of Pharmacy and Technology Management, SVKM’s NMIMS, Shirpur, India 
3
SAAD Centre for Pharmacy and Diabetes, School of Pharmacy and Pharmaceutical Sciences, 
Ulster University, Coleraine, BT52 1SA, Northern Ireland, United Kingdom 
4
School of Pharmacy, Ferris State University, Big Rapids, Michigan 49307 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 2 
 
ABSTRACT 
Diabetes has turned out to be one of the biggest worldwide health and economic burdens, with its 
expanded predominance and high complexity proportion. The quantity of diabetic patients is 
expanding enormously around the world. Several reports have demonstrated the sharp increment 
in the sufferers. Stable and acceptable blood glucose control is fundamental to diminish diabetes-
related complications. Consequently, ceaseless endeavors have been made in antidiabetic drugs, 
treatment strategies, and nanotechnology based products to accomplish better diabetes control. 
The nanocarriers pertaining hypoglycaemics provide improved diabetes management with 
minimum risk of associated side effects. Dendrimers have caught an incredible attention in the 
field of drug delivery and personalized medicines. Dendrimers are three-dimensional well-
defined homogenous nanosized structures consisting tree-like branches. The present review 
highlights the different aspects of dendrimers including fabrication, surface engineering, 
toxicological profile as well as delivery of antidiabetic drugs for the effective cure of diabetes. 
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1. INTRODUCTION 
Diabetes mellitus (DM) is a metabolic disorder that affects billions of people all over the world 
[1, 2]. It is one of the most prevalent life-threatening metabolic disorders, included amid top 3 
non-transmissible disorders, which accounts for more than 80% of non-transmissible ailments 
related deaths and superlative 10 reasons of death around the world. Its worldwide occurrence 
has quickly expanded in recent decades [3]. As per International Diabetes Federation (IDF) 
estimation, more than 96,000 new instances in adolescents and children (less than 15 years age) 
of Type-1 diabetes were identified and analyzed globally each year since 2017. The nations with 
top 10 most noteworthy weight by number are the United Kingdom, United States of America, 
Brazil, India, China, Germany, Russian Federation, Nigeria, Algeria and Saudi Arabia, 
representing about 60% of entire new cases.  
The childrens’ case of Type-1 diabetes differs about 400-fold among countries, rates of age-
adjusted case ranges from 0.1 per 100,000 every year in countries such as China and Venezuela, 
up to 37.8 in Italy (especially Sardinia) and 40.9 per 100,000/year in Finland. In general, North 
America and Europe have higher rate, as the incidences are comparatively low in Africa and 
Asia respectively, with the Kuwait remarkable exception [4].  
"Diabetes" (means a "siphon" or "to go through" which refers to the chronic polyuria, one of the 
prominent characteristics of diabetes) name was conceived from the Greco-Roman doctor, 
Aretaeus of Cappadoccia amid of 30-90 Common Era (CE). The earliest diabetes mellitus 
description originates from the Ebers Papyrus, believed that Egyptian doctor Hesi Ra has written 
about the disease around 1550 Before Common Era (BCE). Indian physicians developed the 
earliest recorded clinical sample for DM. Susruta, the God of Ayurvedic medicines, precisely 
described diabetes in 500-600 BCE. In the subsequent century, Charaka was the first well-known 
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Ayurvedic specialist, recognized the contrast between two types of diabetics. In modern 
medicine the two types are referred as Type-1 DM (T1DM) and Type-2 DM (T2DM) [5, 6].  
Since Banting, MacLeod and Best discovered insulin (a peptide hormone with 51 amino acids 
framing 2 chains A and  B ) in 1921, no further effectual drug that can/may supplant insulin have 
been discovered. Modification of insulin structure during processing, storage and administration 
presents a challenge in insulin storage and diabetes treatment [7-10]. As per International 
Diabetes Federation (IDF) data, about 451 million adult individuals had diabetes in 2017 and it is 
expected to increase to about 693 million in 2045. The number of adolescents and children 
suffering from T1DM (0-19 years) is anticipated to be 1,106,500 around the world. The 
increased T1DM incidence in young age group accounted as 2.4% [11].   
The hyperglycemia (constant) results in interminable macro- and micro-vascular effects, for 
example, cardiovascular complications, nephropathy, neuropathy, retinopathy, and stroke [12]. 
Chronic hyperglycemia (elevated blood sugar level) is related with damage and failure of 
different organ systems, affecting nerves, eyes, heart, kidneys, and may eventually develop 
nephropathies, cerebrovascular infections, neuropathies, ischemic heart sicknesses, retinopathies, 
diabetic foot ulcer and fringe vascular ailments [13-16]. The drugs used in the management of 
hyperglycemic situation in diabetes are classified into two groups based on the route of 
administration, (such as oral hypoglycemics and parenteral insulin) and glucagon-like peptide-1 
(GLP-1) receptor agonists [12]. 
2. PATHOPHYSIOLOGY OF DIABETES MELLITUS 
2.1. Type-1 diabetes mellitus  
Type-1 diabetes mellitus (T1DM) is an insulin-dependent diabetes, resulted from the deficiency 
of insulin due to the progressive deterioration of the pancreatic β-cells by an autoimmune 
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reaction. There are many factors that can either generate or are associated with reaction of 
autoimmune system are, viruses, genetics, dairy animals' milk, and reactive oxygen species or 
free radicals. Histological studies performed on the pancreatic cells of patients with T1DM, 
indicated infiltration of different immunity cells like B and T lymphocytes, dendritic cells, 
macrophages, natural executioner cells, just as islet-responsive antibodies and T-lymphocytes in 
the Langerhans’ islets [17]. The pathogenesis of T1DM is based on the β-cells damage or 
turnover, leading to the release of autoantigens. Thus, β-cells autoimmune-antigens are 
introduced through antigen-presenting cells (APC) to the helper T-cells. In combination of major 
histocompatibility complex (MHC), APC will relocate to the lymph node of the pancreas. 
Autoreactive and autoantibodies T-lymphocyte cells activates in the presence of APC and 
coordinated in contrast to auto-antigens of β-cells [18]. The activated T-cells then encounter 
related β-cell antigens further reactivated once again, consequently killing the β-cells. T-cells 
and macrophages forms cytokines (such as interleukin-22 (IL-22), tumor necrosis factor-β (TNF-
β), and interferon-α (IFN-α)) that results in the improvement of T1DM symptoms [19]. An 
inflammatory reaction may also be induced due to nitric oxide synthase (NOS) generation, and 
development of reactive oxygen species (ROS).  
The reactive oxygen species (ROS) damages β-cells which results in tissue devastation [20, 21]. 
Other than that, the apoptosis-inducing receptors expression, cytokines can activate Fas or 
CD95L-a ligand, type II transmembrane protein belonging to TNF, ultimately result in Fas-
mediated β-cells apoptosis. Likewise, β-cells destroyed when Fas surface ligands came in contact 
of an effector T-lymphocytes. These effector T-lymphocytes facilitates the protease granzymes 
passage via secretion of molecules of perforin (a pore forming cytolytic protein found in the 
granules of cytotoxic T lymphocytes and natural killer cells) [17]. Granzymes destroys these β-
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cells via permitting the pathway of perforin molecules and activates endogenous nucleases. 
Macrophages generate miscible mediator, for example, cytokines and ROS like interferon 
gamma (IFN-γ) and interleukin-1 beta (IL-1β) through lipopolysaccharides and tumor necrosis 
factor-alpha (TNF-α) stimulation and further damages β-cell, which eventually leads to self-
destruction once come in contact with specific environment [20, 21]. During inflammation, β-
cells increment the MHC-II quantity and thus show antigen to the diabetogenic CD4 T-
lymphocytes [20]. Furthermore, numerous chemokines developed in β-cells infiltrates the 
Langerhans islets and employ immune cells to pancreas by means of chemokine receptors [22]. 
Both, natural and versatile immunity contribute to the development of T1DM.  
2.2. Type 2 diabetes mellitus 
Type 2 diabetes mellitus (T2DM) is fundamentally connected with the insulin resistance. Instead 
of solitary "diabetic gene," there seems to be lack of genetic defense that incorporates errors on 
some genes. The estimated post-insulin receptor intracellular errors results in hyper-insulinemia 
and further insulin resistance. Furthermore, T2DM consists of an impaired insulin secretary 
reaction to glucose and diminished insulin adequacy in stimulating glucose take-up through 
skeletal muscles, also in controlling the hepatic production of glucose. This hyperinsulinemia is 
significantly ascribed to obesity (mainly stomach obesity), coronary artery diseases/ailment 
(CAD), hypertension and dyslipidemia [23]. This group of five abnormalities is considered as 
resistance of insulin syndrome, disorder X or Kaplan's disorder. Other factors in the T2DM 
development are age, obesity, and the lifestyle. Chronic viral infections such as [universal 
herpes-type infections, for example, cytomegalovirus infection (CMV), human herpes virus six 
(HHV6) and human herpes virus seven (HHV7)] may sometime also have an influence in 
initiating T2DM. These types of viruses may stay dormant inside the body for several years or 
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decades, however they may turn active later due to maturing, sickness, stress, or poor diet routine 
[5]. Ongoing examination of 2 markers of C-responsive protein, systemic inflammation and IL-6, 
proposes that T2DM could be related with systemic inflammation [24]. It is also demonstrated 
that adults, who gets less than 6.5 hr of sleep/night have a 40% lower insulin affectability than 
adults who get full eight hours of sleep/night. Curtailment in sleep in young adults weakens the 
insulin efficiency to do its work efficiently and can cause hypertension, unusual lipid levels, and 
weight gain [25]. The insulin sensitivity fluctuates with the uptake of starch rich foods, measure 
of physical action and stress signals. A high fatty acid state with hyperglycaemic conditions can 
prompt to decrease the insulin gene expression [26]. Impaired functioning of cholesterol 
transporters can also destroy the β-cells via accumulation of sterol and inflammation in islets 
cells [27]. Fraction of lipoprotein and metabolism of cholesterol leads to the failure of β-cell 
function. The low-density lipoprotein (LDL) experiencing oxidization can diminish the pre-
proinsulin expression in isolated β-cells, while extremely LDL can induce apoptosis of the β-
cells. Conversely, there are reports that analyzed the results uncovering the defensive actions of 
high-density lipoproteisn (HDL) on β-cells. They influence valuably on the glucose homeostasis 
by increasing the function of pancreatic β-cells and disposal of plasma glucose [28].  
Lipid interacts with incretin hormones, especially GLP-1, via down regulating their receptors and 
adjusting the downstream cyclic adenosine monophosphate (cAMP) signaling, along with the 
negative influence on incretin signaling which advances the secretion of insulin and survival of 
β-cells [29]. In addition, unsaturated fats can potentiate the inflammatory toxicity via activating 
specific inflammatory pathways, as fat tissues are essential in generating inflammatory 
mediators, such as TNF-α, Monocyte chemoattractant protein-1 (MCP-1), Plasminogen activator 
inhibitor (PAI-1), Interleukin-6 (IL-6) and IL-1β [30]. Inflammatory mediators enhance the 
 8 
 
immunity cells and inflammatory cytokines production, which results in inflammation of islets in 
the T2DM pancreas in vivo. In in vitro studies a high fat diet feeding, generation of islets 
macrophage migration inhibitory factor (MIF) was expanded which directs β-cells to the 
lipotoxic cell apoptosis [31]. Lipids can also influence the sensitivity of insulin by mounting the 
intracellular di-acylglycerols accumulation; a triacylglycerol compound that shows a negative 
result on signaling of insulin. Moreover, lipids improve protein kinase C proteins, play their role 
in restraining signaling of insulin transduction [32]. Saturated fatty acids (SFAs) activates Toll-
like receptor 4 (TLR4), which consecutively mediated the insulin resistance-related 
inflammation by up-regulating the expression of NF-κB transcription factors, IκB kinase (IKK) 
and pro-inflammatory mediators in fat tissue macrophages [33]. However, it can be deduced that 
inflammation is involved and engaged in the pathogenesis of T1DM and T2DM (Fig. 1). 
  
Fig. 1. Role of inflammation in pathogenesis of T1DM and T2DM 
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3. TYPES OF DIABETES MELLITUS 
It is widely acknowledged that there are three fundamental classes of diabetes, i.e.T1DM, T2DM 
and gestational diabetes (GDM). T2DM establishes 90% of all diabetes cases [34]. 
3.1. Type 1 diabetes  
T1DM is also known and refereed as juvenile-onset diabetes, juvenile diabetes, ketosis-prone 
diabetes, brittle diabetes, insulin-dependent or immune-mediated. It is brought about by an auto-
immune response, where the body's immune system attacks insulin-generating cells. Individuals 
with T1DM produces no or negligible amount of insulin. The disorder can influence people of all 
age group; however, it is more often observed in young adults or children [35]. Insulin treatment 
is required for T1DM, despite the fact that the disease may develop at any age, it usually attacks 
adolescence or childhood and the prevalent diabetes type analyzed before the age of 30. 
Exemplary indications of T1DM include: more thirst (polydipsia), more urination (polyuria), 
increased hunger, rapid weight loss, vision changes and fatigue. If T1DM left unmanaged, 
people can succumb to diabetic keto acidosis, which may lead to death or coma [5].  
Recent development in the area of role of microbiota uncovers the emergence of gut microbiota 
as the main source in the progression of an autoimmune disorder, including T1DM. Mutually 
with the intrinsic immunity, gut microbiota acted on path recognition receptors (PRR) and directs 
the native inflammatory reaction. The PRR perceives pathogen-associated molecular pattern 
(PAMPs) and promote the induction of native immune reaction leading to pro-inflammatory 
cytokines, advances autophagy, interferons and phagocytosis activity that encourages the 
eventual cell death. For example, toll-like receptors (TLR) 7, TLR-8, Myeloid differentiation 
primary response protein (MyD88), and NLPR3 gene are responsible for T1DM predisposing 
[36].  
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A strong correlation between T1DM analyzed before the age of 30 and explicit HLA-D (human 
leukocyte antigen type D) phenotypes such as HLA-DR3/DR4, HLA-DR3 and HLA-DR4 was 
observed in Caucasian population [37]. Of individuals recently diagnosed with T1DM, 70-80% 
consists of antibodies for their islet cells, 30-50% with antibodies for insulin, and 80-95% 
comprises antibodies for glutamic acid decarboxylase (GAD), which is an enzyme required by 
beta cells of pancreas to function efficiently [38]. Infection caused by Coxsackie B4 virus play 
its role in the T1DM development by provoking the autoantibodies generation targeting GAD, as 
a small region of GAD molecule is almost identical to a protein region found on the virus. . 
Studies in diabetes-inclined rodents demonstrate that retaining soy and wheat may help to 
prevent or delay the onset of diabetes [33]. The O2 free radicals developed as a result of the 
numerous chemical and metabolic reactions in body, destroys own body cells and islet cells, 
which have low enzyme level that can separate the free radicals. In this way, factors that can 
induce the endogenous production of free radicals (such as, air contamination, unhealth dietary 
habits, and smoking) may damage pancreatic cells. Likewise, there are many chemicals agents 
that can contribute towards the development of T1DM, for example, pyriminil, a rodent toxin, 
and two physicians endorsed drugs, L-asparaginase and pentamidine.  
3.2. Type 2 Diabetes  
T2DM is determined by insulin resistance and decrease of insulin production [6]. In T2DM or 
non-insulin dependent diabetes (NIDDM), the pancreas still forms the insulin. The concern is 
unresponsiveness of the insulin receptors which eventually causes inefficient hepatic metabolism 
of glucose. This is alluded to as insulin resistance. In this situation, pancreas produces more 
insulin to regulate high blood glucose level. Although, the cells are not able to respond, therefore 
the blood glucose level remains high. After some time, this elevated level of blood glucose starts 
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to harm the body by the accumulation of glycation and sorbitol proteins, causing indications like 
exhaustion, nocturia, general malaise, consistent thirst, unexpected weight reduction, vision 
changes (blurring or poor centering), diminished immunity, slow mending capacity from wounds 
or cuts. When this remains untreated, the damage caused by T2DM become irreversible, 
prompting perpetual health issues, for example, renal disappointment, visual deficiency, and 
vascular trade off.  
T2DM is described as a dynamic decrease in pancreatic β-cell activity and expanded insulin 
obstruction, and records for around 90% of individuals with DM [40]. T2DM have seen highest 
increase in prevalence, generally determined by lifestyle incorporating changes in dietary habit 
and patterns, declining physical movement level, and expanding sedentary practices [41]. T2DM 
is also known as ketosis-resistance diabetes and maturity onset diabetes (MOD) [5]. This is the 
most widely recognized type of diabetes analyzed in individuals who are 30 years of age or 
older. It might happen in children or adolescents and alluded to as maturity onset diabetes in 
young (MODY). Although, most of the patients were managed with exercise, eating healthy diet, 
and oral medications, some patients may persistently or intermittently needs insulin to regulate 
the symptomatic hyperglycemia and avoid non-ketotic hyperglycemic hyperosmolar coma 
(NKHHC) [37].  
3.3. Gestational diabetes  
Gestational diabetes (GDM) referred to diabetic conditions analyzed only during the gestation 
period or pregnancy. Gestational diabetes is observed in 2-5% cases of all pregnancies. Despite 
the fact that this type of diabetes may immediately remit after the childbirth, if ignored or left 
untreated, it may cause stillbirth, macrosomia, fetal respiratory distress and birth defects. 
Likewise, it may incline both infant and mother to developT2DM later on [5]. One out of six live 
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births happen in women with DM, of which the most general type accounts for around 87.5% of 
all diabetes during pregnancy is GDM. Offspring risks include high adiposity, birthweight and 
macrosomia that is large for gestational age (LGA). Though, severe perinatal difficulties (for 
example, shoulder dystocia, death, fracture or nerve paralysis) are uncommon (1-4%), 
macrosomia (newborn child birth weight >4 kg) and large for gestational age (birth weight 
>90%) are normal, influencing 10-20% of neonates birth to women with GDM [42].  
The hereditary premise of T2DM is unknown yet; several further types have been genetically 
analyzed. The most widely recognized type is MODY, a familial type of diabetes acquired in an 
autosomal predominant way and related with mutations in certain hepatic genes or β-cell (for 
example glucokinase and HNF homeobox A (HNF-1a)). Further, a well-described type of 
diabetes (secondary DM) involve diabetes related with pancreatic infection (for example 
haemochromatosis-associated diabetes), corticosteroid (or other) hormone extremes or definite 
drug (for example, protease inhibitors in human immunodeficiency virus (HIV) infection, 
immune checkpoint inhibitors in tumor treatment, and a typical antipsychotic drug in 
schizophrenia management) [43]. 
4. DENDRIMERS AS FUTURE SMART DRUG CARRIERS FOR THE MANAGEMENT 
OF DIABETES MELLITUS 
4.1. Dendrimers 
Dendrimers are homogenous well-defined 3D structure having tree-like branches [44, 45]. 
Dendrimers have caught an extraordinary attention in the drug delivery field to achieve 
controlled drug delivery and in development of modified medicine systems [46]. In 1978, Vogtle 
et al. made the first endeavor to design and develop the dendritic framework [47]. These 
molecules were primarily referred as "cascade molecules". Tomalia et al, established another 
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class of cascade molecules with amides, with small structures [48]. They refereed these 
innovative dendritic macromolecules as "dendrimers". The name dendrimer is derived from the 
Greek words "dendros", signifies "branch or tree" and "meros" means "part" [49]. Meanwhile, 
Newkome and co-workers studied synthesis of analogous macromolecules and named 
"arborols", based on “arbor”, which is a Latin word for tree [50]. 
Dendrimers are monodispersed, nanoscopic systems, and commonly referred as homogeneous 
[51]. In 1985, Donald A. Tomalia introduced poly(amidoamine) (PAMAM) dendrimer. Tomalia 
coined 'starburst polymers' as a new polymers class. This imperative contribution of Tomalia and 
co-workers opened up a whole new explorative field of nanotechnology [52]. Dendrimer shows a 
rising class of low polydispersity and hyperbranched macromolecules that presents unique 
highlights, for example, noteworthy control on molecule size, great branching density, nanoscale 
size and high surface functional groups [52, 53]. Dendrimers represent more diversity of 
chemical structure, as poly(etherhydroxylamine) (PEHAM), poly(propylenimine) (PPI), 
poly(amidoamine) (PAMAM) and poly(L-lysine) (PLL) and polyester dendrimers [54-56]. 
Dendrimers show impressively improved chemical and physical properties in contrast to the 
conventional direct polymers. Dendrimers have various noteworthy properties that makes them 
more interesting such as (i) potential to encapsulate drugs with poor solubility profile within the 
inner cavities, (ii) nanosize and short polydispersity index (PDI) of dendrimer, take-up by the 
reticuloendothelial framework can be kept away, (iii) better solvency, retention effect and 
penetrability, (iv) neutral and anionic surface dendrimers makes them less cytotoxic and low 
visual irritation, (v) targeting efficacy, (vi) biocompatibility, and (vii) manageable periphery 
charge [57, 58]. 
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Numerous investigations revealed that dendrimers can be used for many purposes, for example, 
in delivery of drugs, genes, antioxidants, peptides, and in biomedical imaging. Dendrimers 
include a nanoscopic class of compounds, with characteristic monodispersed and homogeneous 
molecular structure. Being referred as fourth and most up to date polymers class [59, 60], these 
dendrimers vary from the traditional oligomers/polymers because of their symmetry, great 
branching, and a high end-functional density.  
There are several methodologies for dendrimer fabrication, however divergent and convergent 
techniques are more commonly utilized methods [45, 61]. Over the most recent decade, new 
methods have been introduced, for example, lego chemistry, joined convergent-divergent, hyper 
cores, click synthesis method, double exponential and branched monomers method [62, 63]. To 
date, more than 50 dendrimers families exist, with different and unique properties, since the 
interior, surface and center can be designed for different types of dendrimer application [64].  
4.1.1 Comparative account of linear polymer, dendritic polymer and dendrimers 
Linear polymer does not have branched structure and shows better thermostability over the 
branched (or cross-linked) polymer, which demonstrates that ladder type structure of polymer 
successfully expands the thermal stability [61].  
Dendritic polymers are new class of synthetic polymers derived by structures reminiscent of 
trees. These are diversified, highly branched structures supporting the cavities formation and thus 
recent encapsulation properties for different organic and inorganic molecules. Dendritic 
polymers do not possess the perfect dendrimer branched structure; they can be easier to prepare 
and still maintain most of the positive dendrimer attributes, such as high surface functionality. 
Appropriate chemical functionalization gives proper structural features, for example polarity, 
flexibility, and potential intermolecular interactions with these substances [45]. Dendritic 
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polymers considered as branched polymeric architectures, are classified into random 
hyperbranched polymers, dendrigraft polymers, dendrons, and dendrimers based on degree of 
structural control [55]. In general, branched polymers have sophisticated topological structures 
and exciting physico-chemical and biological properties. In comparison to their linear analogues, 
branched polymers have three-dimensional globular structure, lower solution/ melting viscosity, 
smaller hydrodynamic radius, higher degree of functionality, increased encapsulation 
capabilities, enhanced solubility and minimal molecular entanglement. 
Dendrigraft polymers have less controlled structures. The branching densities cannot be 
determined exactly, they are somewhat arbitrary and difficult to control. Dendrigraft polymers 
are having more flexible and extended structures. They exhibit unique and different properties 
compared to the more compact traditional dendrimers. Dendrigraft polymers can be generated 
through ionic polymerization by combining the features common to dendrimers and random 
hyperbranched polymers [45].  
Dendrimers are artificial polymers with interesting structural properties which have been 
broadly explored for their biomedical applications, particularly in drug delivery [46]. 
Monodisperse nature of dendrimers, in addition, provides reproducible pharmacokinetic behavior 
as compared to linear polymers, which are generally polydisperse and thus containing varying 
molecular weighed fractions among a given sample. Also, controlled globular shape of 
dendrimers other than entangled and coiled structures of linear polymers enhances their 
biological properties [58]. Furthermore, prospect of surface engineering due their high density of 
functionalities allow to tune their thermal, mechanical, rheological, solution properties (size, 
conformation, solubility), and biocompatibility. These features can further improve the 
biodistribution and pharmacokinetic profile, tendency of crossing biological barriers, and blood 
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circulation time [61, 62]. Different properties of linear polymer, hyper-branched polymer and 
dendrimer are represented in Table 1. 
Table 1: Various properties of linear polymer, hyper-branched polymer and dendrimer 
Properties Linear Polymer Hyper-branched Polymer Dendrimer 
Structure 
 
 
 
Topology 3D, irregular 3D, regular 1D, linear 
Synthesis One-step, relatively 
facile 
Multiple-step, laborious One-step, facile 
Purification Precipitation   Chromatography Precipitation 
Scaling-up Already, easy Difficult Already, easy 
Molecular weight Discrepant Identical Discrepant 
Polydispersity 
index 
>1.1 1.0 (<1.05) >1.1 
Degree of 
branching 
0.4-0.6 1.0 0 
Entanglement Weak Very weak or no Strong 
Viscosity Low Very low High 
Solubility High High Low  
Functional group At linear and terminal 
units 
On periphery (terminal 
units) 
At two ends 
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Reactivity High High Low 
Strength Low Very low High 
 
4.2. Structure of Dendrimers  
The dendrimers structures are made up of multifunctional core, which permits the branch 
coupling, repeated branches layers originated from core known as dendrons and functional 
groups are present on the surface [65-67]. The first union consisting of a core substituted with 
dendrons leads to the first generation of the dendrimers. By increasing the number of branches in 
the structure of dendrimer, a higher generation of dendrimer can be acquired. Hence, the second 
layer of repeated units prompts the second generation of dendrimer and thus afterwards. With 
respect to the dendrimer fabrication, these compounds can be synthesized mainly by convergent 
or divergent methodologies [48]. Generally, surface groups are either neutral, or charged 
(anionic/cationic) and the toxicity results showed that cationic dendrimers are most cytotoxic 
among all the dendrimers [68]. To address the challenge of cytotoxicity incited with dendrimers, 
different approaches have been proposed dependent on the suppression of cationic surface, 
which can be achieved via chemical adjustment, PEGylation and acetylation with neutral or 
anionic compounds. It is likewise essential to accentuate the multifunctional dendrimers 
character, permit the linkage of various ligands of numerous receptors, accomplishing the 
selectivity along with even synergistic impact [69, 70]. Covalently planned dendritic 
macromolecules demonstrate the advantage of progressive control over the drug release [71].  
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Fig. 2. Typical dendrimer structure 
4.3. Types of Dendrimers  
4.3.1. Poly (propylene imine) dendrimers  
Poly(propylene imine) (PPI) is the earliest known dendrimer presented by Vogtle defining the 
propylamine spacer moieties. Generally, comprised of poly-alkylamines with primary amines 
end groups and inside is comprised of some of tertiary tris-propyleneamines. These types of 
dendrimers have been examined in organic and material sciences. Occasionally, "diamino 
butane" (DAB) and "polypropylene amine" (POPAM) dendrimer are likewise utilized as another 
term for PPI dendrimers. Its subdivision is Polyethylene imine (PEI) dendrimers, comprised of 
diamino propane or diaminoethane as central core's functional group [72].  
4.3.2. Poly(amidoamine) dendrimers  
Poly(amidoamine) (PAMAM) is a class of dendrimer consisting tertiary amines and polyamide 
as branching points. Tomalia and colleagues presented PAMAM dendrimers in mid-1980s later 
than they were considered broadly by scientists. "Starburst" dendrimers, the PAMAM sub-class 
trademark consist of tris-aminoethylene-imine group as center core. This name was given 
because of their star-like outer shell of high-generation of dendrimer structure when examined 
2D [72].  
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4.3.3. Frechet-type dendrimers  
Frechet-type dendrimers are the type of dendrimer, establish by Hawker and Frechet with hyper-
branched engineering of poly-benzyl ether. It includes carboxyl (–COOH) as end groups and 
consequently offering superior branching point intended for modulation of functionalization of 
end groups. Likewise, the existence of these polar end groups helps to increase the solubility of 
this dendrimers in aqueous and polar media [44].  
4.3.4. Core shell tecto-dendrimer  
Core shell tecto-dendrimers are the dendritic structures where dendrimer molecule is utilized as a 
center encompassed covalently through different dendrimers shell. As a rule, the center 
generation number is greater than the encompassing dendrimers. The connection of extra shells 
is constrained by engineered techniques permitting development of nanoscale area of 1–100 nm 
[72].  
4.3.5. Chiral dendrimers  
Chiral dendrimers are fabricated by utilizing intrinsically differentiating branches, chemically 
related to the chiral center. Chirality is crucial, besides the axis of functional groups. Seebach 
and coauthors fabricated chiral dendrimers to examine the impact of chiral building blocks on the 
dendritic structure's chirality. Moreover, to show the likelihood of enantio particular 
complexation of host with these models [73]. The chirality and optical property of dendrimers 
involves chiral center diminished with increment in dendrimer size. As of now, numerous 
researchers are dealing with the advancement of chiral dendrimers [72].  
4.3.6. Liquid crystalline dendrimers  
The fabrication of liquid crystals has probable industrial applications and has been determined by 
many analysts. These dendrimers are comprised of mesogenic liquid crystalline monomers. The 
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liquid crystalline mesophages or phages are developed by molecules are generally disk-like 
(discotic) or rod-like (calamitic) for example, carbosilane dendrimers have mesogenic functional 
groups, for example, cholesteryl and cyanobiphenyl. The racemic AB2 rod synthesis like 
mesogenic monomer depends on conformational isomerism, 13-hydroxy-1-(4-hydroxyphenyl)- 
2-(4-hydroxy-4″-p-te-henylyl) tridecan, and formation of its initial four dendrimers and 
monodendrons generations via convergent method is determined by Percec and co-workers [74].  
Pedziwiatr-Werbicka and collaborators estimated the capability of amino ended carbosilane 
dendrimers to convey short chain of siRNA in the form of dendriplex, which was found to be 
least cytotoxic for blood cells as compared to the parent dendrimers suggesting its activity in the 
bioactives delivery [75].  
4.3.7. Peptide dendrimers 
Peptide dendrimers are spiral or wedge-like branched macromolecular framework containing 
peptidyl branching center and covalently bonded end-functionalized groups. These peptide 
dendrimers are fabricated by convergent and divergent technique for production. These have 
been examined for many biochemical and biotechnological application because of their precise 
composition and simplicity in production. These dendrimers discover their application as 
surfactants and in biomedical science field as various peptides antigen, protein mimics and 
transporter for gene and drug delivery. Darbre and Reymond utilized these dendrimers as catalyst 
of esterase [76].  
4.3.8. Multiple antigen peptide dendrimers  
Tam has reported the multiple antigen peptide (MAP) dendrimer, constructed by utilizing 
skeleton of polylysine. The branching points in the dendrimer structure are presented utilizing 
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alkyl amino unit of monomer lysine side-chain. These dendrimer has been examined broadly in 
biomedical science involving diagnostic and antibody study [77].  
4.3.9. Glycodendrimers  
These dendrimers are the monodispersed macromolecule of dendritic framework involving CO2 
moiety. The vast majority of glycodendrimers concludes saccharide buildup groups of terminal 
and sugar units in the core. CO2 centered, CO2-based, and CO2 coated dendrimers are the three 
kinds of glycodendrimers classifications [57], that shows a better relationship with lectins joined 
frameworks than mono-CO2 attached frameworks. They are utilized in site-explicit delivery of 
drug aimed to the organs with rich-lectin.  
4.3.10. Hybrid dendrimers  
Hybrid dendrimers is a mixture of dendritic and straight polymers, present in hybrid block form 
or grafted copolymer. Dendritic hybrids are probably framed because of their circular shape and 
extensive quantity of end-functional groups present on dendrimers. Relationship of the little 
dendritic piece to the different responsive chain ends makes them widely used for many 
applications such as surface active agents, compatibilizers or adhesives, or hybrid linear dendritic 
polymers. Dendritic hybrids have a reduced, unbending, consistently formed globular structure, 
investigated for different perspectives in the drug delivery field [78, 79].  
4.3.11. Polyester dendrimers  
The advancement of drugs therapeutic index (TI) is a critical field in diseases like malignant 
growth, incendiary and different infectious ailments like HIV. These dendrimers are confident 
here because of its biodegradable and biocompatible properties. As a result of less exposure of 
drug to healthy tissue, shows less toxicity in contrast to other dendrimers which is an ideal 
property for any compounds to be used in drug delivery. These dendrimers consist of inner void 
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spaces undifferentiated from parent dendrimers and hence may be utilized as a nanocarrier for 
small molecular drugs, imaging moieties or metals [80-82]. The reactive surface of these 
dendrimers can be modified to accomplish the targeted delivery, enhanced biological 
distribution, controlled and balanced release of the encapsulated drugs.  
4.4. Properties of Dendrimers  
Dendrimers are based on their specific nature from intricate resources and their examination 
converge the exploration fields of both polymer science and organic chemistry. With a 
developing enthusiasm for finding and using the dendrimers for novel applications, particularly 
in biomedical sciences, a huge tool compartment of characterization methods is essential to 
satisfy the stringent quality requirements for such applications. The difficulty caused in 
determining these materials is frequently an outcome of the similar distinguishing characteristics 
that make them attractive for broad applications: their definite building, monotonous and layered 
structure, huge number of functionalized groups, and globular structure in solution. The 
foundation in dendrimer science is the amalgamation of monodisperse dendrimers, depends on 
total substitution of the functionalized groups. This is particularly essential for most 
progressively prevalent divergently developed dendrimers, where the quantity of concurrent 
responses that must be performed increments for every generation and where division of 
defective structures is troublesome because of the little polarity and size contrast among 
completely and incompletely responded dendrimers. Convergently developed dendrimers, 
require lesser number of synchronous responses to be performed amid each generational step, 
and have a lot bigger contrasts in size between the completely reactive structure and partially 
reactive molecule, and as an outcome their partition is easier. A mistake in the convergent 
synthesis results in a totally missing arm of the dendrimer when contrasted with the minor errors 
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happening in the divergent case. Thus, reliable techniques for characterizing the response 
progress, the kind and number of terminal groups, just as the purity of the last product are crucial 
in dendrimer research [83-86].  
4.5. Methods of Synthesis of Dendrimers 
4.5.1. Divergent synthesis 
The divergent synthesis includes the dendrimer development beginning from the center and 
working up the molecule to the outer surface in a stepwise manner utilizing dual essential 
activities. In each stage, a novel layer of branching unit is included, which causes increment by 
one number of generation in the dendrimer structure. In the main activity, monomer is coupled 
later the monomer end-assemble is deprotected or changed to make another receptive surface and 
after that coupling of another monomer, and so on. It is raising combination of dendrimers. In 
spite of being a the very fundamental method, this methodology requires extremely compelling 
responses to evade mistakes in the dendrimer structure in light of the fact that expanding number 
of responses must occur simultaneously with expanding generations. Different dendrimer 
structures can be worked among divergent strategies such as phosphorus-based dendrimers, PPI, 
and PAMAM dendrimers.  
The divergent dendrimer strategy presents two fundamental challenges. First, the quantity of 
response focuses rises rapidly amid the formation which causes an increment in the response 
focuses and in molecular weight. This prompts slower response energy and thereby making it 
hard to make higher generation of dendritic system. This prompts expanding deletions amid the 
dendrimer growth causing various imperfections in the dendrimers of higher generation. Besides, 
the partition of the ideal product from reactants or ''cancellation products'' ends up difficult 
because of high molecular resemblance among desirable and obtained results. Notwithstanding 
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these disadvantages the divergent approach has been practical in the formation of various 
dendrimer structures [87].  
4.5.2. Convergent synthesis  
The convergent technique begins at the periphery and continues towards the center for the most 
part coordinated monomers coupling. A small dendron is fabricated in the starting by connecting 
two groups at periphery to the branching unit. Afterwards, the two dendrons are connected to the 
branching unit to frame a dendron of subsequent higher generation. This coupling procedure 
continued causing multiplying the dendron size every time. In the last stage of the convergent 
method, core is framed in the last step and at least two dendritic portions (dendrons) are 
consolidated at the center prompting the development of dendrimer. In this methodology, 
auxiliary imperfections can be absolutely bypassed since, the quantity of responding accomplices 
does not change on expanding generations. The quantity of receptive locales stays negligible 
amid the united generation process which prompts quicker response yields and rates. It decreases 
the production of dendrimers. Notwithstanding, significant limitation of this technique is the low 
yield in the combination of higher dendrimers generation and henceforth favored for the 
development of lower age dendrimers. Dendritic structure formed by convergent strategies is 
poly (aryl ether) system (Frechet-type) [50]. The schematic portrayal of synthesis strategies for 
dendrimers is presented in Fig. 3.  
4.5.3. Hyper cores and branched monomer development  
The oligomeric moieties are recently amassed and afterward can be connected together to frame 
dendrimers in moderately some stages with higher yields [57]. The schematic portrayal of hyper 
centers and monomer branched development is given in Fig. 3c.  
4.5.4. Double exponential development  
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It is practically same as quick development strategy for linear polymers. In this technique, the 
monomers for divergent and convergent development are set up from a solitary beginning 
material. The subsequent two materials are then responded together to give symmetrically 
ensured trimer. This is then utilized for repeating the dendrimer development. Because of quick 
production feature of the double exponential development approach, it may be effectively 
coupled with divergent or convergent development [88].  
 
  
Fig. 3. Common methods of synthesis of dendrimer (a) Divergent (b) Convergent and (c) 
Hyper cores and branched monomer development [72, 57] 
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4.5.5. Lego chemistry 
In lego science, centers and branched monomers with progressively functionalized groups, are 
utilized to form phosphorous dendrimers. After couple of varieties when all is said in done 
engineered planning plan, the set up plan grants multiplications of the quantity of surface 
dendrimer groups from 48 to 250 out of a solitary advance. Least prerequisite of solvent, 
simplistic purification probability and development of earth minding side-effects, for example, 
nitrogen and water are the main highlights of this method [72].  
4.5.6. Click chemistry 
It is one of the imperative high yielding reactions. Hence, this method has been utilized in 
amalgamation of numerous new dendritic structures. The strategy is to fabricate carbon-rich 
dendrimers and natural friendliness. Thiol-yne click responses (TYC), copper-helped azide-
alkyne cyclo expansion (CuAAC) [89-91], and thiol-ene click response (TEC) [90, 92] is portion 
of the generally utilized click responses in the amalgamation of dendrimer. Aside from these 
responses, new responses are being investigated to additionally enhance the dendritic design 
[93]. Staudinger response was adjusted to give "click" components. A "Janus" and an "onion 
peel" dendrimer [94] were formed with this new response. Trans-cyclooctene/tetrazine [95] pair 
and the Sharpless' new SuFEx response [96] are a portion of alternate responses that shows click 
qualities and could be utilized for dendrimer fabrication [97, 98]. Mullen et al united folic acid 
conjugated dendrimer by means of fluoresce in isothiocyanate conjugated dendrimer and showed 
their receptor based targeting property and fluorescence imaging property. These dendritic units 
were coupled by utilizing 1,3-dipolar cycloaddition response (click science) amid an azide and 
alkyne surface groups of first and second dendrimer, respectively. In an in vitro study done on 
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human epithelial malignant growth cell line, it was reported that this coupled dendrimer module 
can target the over-expression of folic acid receptor [99]. 
5. DENDRIMERS MEDIATED ANTI-DIABETIC DRUG DELIVERY  
5.1. PAMAM dendrimer 
Labieniec et al. examined that PAMAM G4 suppresses the plasma hyperglycaemia in diabetic 
rodents, result in decreased glycoxidation and post-synthetic non-enzymatic alteration of 
biomacromolecules in sustained streptozotocin-diabetic rodents. In spite of glucose, additional 
triglycerides and plasma cholesterol, increased in diabetic individuals, reduced upon PAMAM 
G4 direction [100]. Boas and Heegaard uncovered that the absence of lytic poisonous quality of 
PAMAM dendrimers up to the fifth era, when surrendered at dosages of 10 mg kg
−1
 to mice 
[101].  
Diabetes-induced damage identified with hyperglycaemia is related to the impaired 
mitochondrial function. Despite their cytotoxicity, PAMAM G4 dendrimers lowers or suppress 
sustained markers and plasma glucose of diabetic hyperglycaemia in an experimental diabetic 
animal model [102].  
Nowacka and associates examined differential scanning calorimetry (DSC) sequences of various 
PAMAM dendrimer generations and predicted that at the lower convergence of G3 and G4 
dendrimers (0.06 mol/l), the region under the main peak (at 60°C) diminished while, it expanded 
under the second peak. Consequences of Thioflavin T (ThT) fluorescence demonstrated that in 
nearness of G3 and G4 PAMAM dendrimers, at lower concentration the procedure of fibril 
development is backed off, yet the last measure of fibrils was same as for insulin in the absence 
of dendrimers. Lower dendrimers concentration can more readily secure the proteins structures. 
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It is also shown that the individual fibrils packs included 2-5 filaments curved together, their 
gross distance across being about 12- 20 nm [103].  
Akhtar et al. demonstrated that, at low concentrations (1 or 5 mg/kg) PAMAM-induced 
variations in Mitogen-activated protein kinase (MAPKs) in the diabetic kidneys happened 
autonomously of EGFR, accordingly suggesting that PAMAMs can prompt uncoupling of 
MAPK signaling from EGFR at least in this infected state. Additionally, the reality the 
dendrimer-initiated changes in estimated glomerular filtration rate (eGFR) and p38 MAPK 
signaling in the segregated ordinary kidney could be turned around by antioxidant treatment 
recommends that Superfect (SF) and Polyfect (PF) PAMAM dendrimers balanced signaling of 
MAPK by means of an oxidative-stress dependent manner/pathway [104].  
Araujo et al. work reported that not just 99% of PAMAM-CNT-miR-503 framework transfection 
adequacy, but additionally exceedingly effective micro Ribonucleic acids (miRNA) discharge in 
endothelial cells, being thusly ready to control the cell multiplication population. The miR-503 
stability towards RNAse was likewise significantly increased. At last, the quantity of vessels on a 
sponge model subcutaneous embed on mice managed with PAMAM-CNT-miR-503 was 
altogether decreased when contrasted with both the free and the control miR-503 [70].  
Dong et al. decided that both the plasma insulin and glucose levels focuses in rodents 
administered with PAMAM dendrimers and exhibited that the operators adequately expanded the 
pneumonic retention of insulin with no membrane harm to the respiratory tissues. This 
astounding hypoglycaemic impact, seen after pneumonic organization of insulin with PAMAM 
dendrimers, demonstrates that dendrimers may perhaps be utilized as transporters in anti-diabetic 
treatment [105]. Labieniec-Watala proposed that various metabolic impairments of untreated and 
durable exploratory Streptozotocin (STZ)-induced DM in rodents can be viably diminished and 
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controlled by the means of subcutaneous or intraperitoneal infusion of PAMAM dendrimers 
[106]. Siewiera and Labieniec-Watala research dependent on PAMAM G3 dendrimer 
effectiveness to enhance the weakened breath of rodent heart mitochondria. They uncovered that 
dendrimer G3 (20 mg/kg body weight) is poisonous and has a high mortality among the animals 
controlled with G3 did not permit to play out a dependable result investigation [107].  
5.2. Triazine dendrimers  
Fluorescence-based glucose observing systems, in light of an aggressive restricting association 
between concanavalin A (Con An) and CO2, for example, glucose, dextran, and mannose, are 
non-obtrusive, and offer an open door for continuous blood glucose monitoring [108]. A triazine 
dendrimer having 12 groups of glucose arranged and examined for an aggressive restricting 
measure with a fluorescently-marked Con A. To assess its potential as an implantable sensor, a 
microporous polyethylene glycol (PEG) based hydrogel circle bearing the dye marked Con An 
and glycosylated triazine dendrimer was intensely titrated using glucose. The fluorescence power 
titration plot against glucose focus seemed linear inside the concentration of glucose 50–200 
mg/dL with an affectability of 1.3% per 10 mg/dL [109].  
5.3. Cationic dendrimers  
The advancement of a productive strategy to enhance the injury healing process is critically 
required for diabetic patients enduring risk of appendage removals. Different development 
factors have been introduced for the management; in any case, more research still must be done 
to keep up their healing impact. Kwon et al. built up an advance cationic dendrimer, L-arginine-
joined poly-amidoamine (PAM-RG4), for the safe and effective DNA conveyance. Since, the 
PAM-RG4 interior comprises of an exceedingly requested PAMAM dendrimer base, PAM-RG4 
demonstrates a limited conveyance of molecular loads [Mn=22 560; PD (Mw/Mn)=1.063] and 
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comparing uniform physicochemical characteristics. Furthermore, 62 arginine buildups on the 
PAM-RG4 surface and give more effectiveness of cell delivery. Consequently, it is found that 
effective multiplying cells in wound tissue were proficiently transfected, bringing about a high 
state of vascular endothelial growth factor (VEGF) expression. Six days post injection, diabetic 
mice skin wounds were commonly mended and shown a well-arranged dermal structure, which 
was further affirmed by histological stain [110].  
6. TOXICOLOGICAL ASPECTS OF DENDRIMERS  
Akhtar and collaborators found that intense in vivo administration of cationic PAMAM 
dendrimer (naked) delivery frameworks, at doses that don't indicate net poisonous quality (at the 
morphology of kidney level), can inherently balance renal signaling of MAPK-an essential cell 
signal transduction path [104].  
Labieniec et al. showed that most of the respiratory parameters of mitochondria were lesser in 
rodents with diabetes in contrast to the control non-diabetic animals, which implies that the 
mitochondrial breath limit under diabetic conditions is unequivocally hindered. Regardless of the 
useful impacts of dendrimers on glycaemic control, these specialists weakened the capacity of 
heart mitochondria, to a considerably greater degree as of diabetes itself. This implies paying 
little attention to normalizing the signs of diabetes seriousness, PAMAM G4 did not re-establish 
the heart mitochondrial breath limit evidently diminished in diabetic rodents, which may point to 
a lethal impact of the PAMAM dendrimers on heart mitochondria [102].  
7. SURFACE ENGINEERING OF DENDRIMERS  
Chemically, the drug molecules conjugate with dendrimer surface or encapsulate physically 
within the core of dendrimer. When functionalized groups are initiated before coupling, a great 
coupling efficacy might be accomplished. Frequent structural units present in drug polymers and 
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molecules are carboxyl (COOH), hydroxyl (OH), thiol (SH), guanidine (CH5N3) and primary 
amine (NH2). The hydroxyl groups can be changed over to dynamic intermediates supporting the 
nucleophilic responses. Sometimes, the direct coupling might prompt the drugs deactivation, 
with the goal that the prodrugs won't have any therapeutic impact in anticipation of divided from 
the holding. The spacer of two functional groups can be acquainted with the targeted delivery or 
controlled release of therapeutic drugs to form bonds that are enzyme-cleavable or hydrolysable 
in vivo [111]. 
Dendrimer as core and surface can be tailored using phosphate, amino acids, folate, fluorine, 
antibody, lipids or RGD (Arg-Gly-Asp). Fluorinated dendrimers shows great small interfering 
Ribonucleic acid (siRNA) loading capability and electronegativity. Amino acid modified 
dendrimers are synthesized using endogenous proteins; which improves dendrimer endosomal 
getaway and biocompatibility. Carbosilane dendrimers raise the ability of tissue’s gene 
transfection to be managed. Phosphate dendrimers have hydrophobic base and the surface is 
hydrophilic which increases their permeability for the targeted tissue. Lipid based dendrimer 
undergoes endosomal escape and enhances the dendrimers permeability. Specific tissues 
targeting achieved via coupling dendrimer by RGD, folate and definite antibody, thus falling off 
target consequence [112, 113]. 
The surface engineering of dendrimers is convenient and a graceful approach that covers the 
dendrimer with positive charge makes it more biomimetic nanocarriers and alters the biological 
and physicochemical properties of dendrimers. Therefore, dendrimers surface engineering 
chemistry holds an assurance in the advanced drug encapsulation, solubilization, modified gene 
transfection, controlled and sustained drug release and intracellular targeting in the investigative 
field. Multifunctional dendrimer development have promising applications in biomedicines 
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because targeting ligands quantity determines the narrowness in the similar manner as further 
kind of group will secure the stability in the biological environment and extended distribution, 
while others assist their delivery via cell membranes [114]. 
7.1. Fluorophore-modified dendrimers 
PAMAM dendrimers engineered using fluorescence dye, Oregon Green 488, allows the vector 
visualization during transfection of gene. Unexpectedly, the fluorophore-engineered dendrimer 
represents greater transfection property as compared to not modified dendrimer, which is similar 
to 3 commercial transfection compounds and involves Lipofectin, Lipofectamine and SuperFect. 
The unpredictable elevated fluorophore-modified dendrimer transfection efficacy is accredited to 
water resistant property of the fluorescent dye [115, 116]. 
7.2. Aminoglycoside-modified dendrimers  
Aminoglycosides, small molecule antibiotics class with for siRNA and DNA biological affinity. 
These agents are capable to reconcile the macromolecules cellular uptake based on the 
transporter valency. Aminoglycosides conjugation like neomycin, neamine, and paromomycin, 
to PAMAM dendrimer appreciably modifies their transfection efficiency. Also, the 
aminoglycoside-engineered dendrimers can also proceed as antibacterial reagents [115]. 
The toxic PAMAM dendrimers can gradually turned to be “more friendly” and safer for cellular 
environment on enduring non enzymatic N-glycosylation in existence of extreme glucose (like in 
severe hyperglycaemia or diabetes conditions). Labieniec et al., have shown that trial model of 
streptozotocin-caused diabetes in rodents: higher the hyperglycaemia extents in diabetic animals 
revealed as more protective for the analyzed toxicity of PAMAM [100]. 
For dendrimers, N-glycosylated or glycated dendrimers becomes the final product in the non-
enzymatic glycosylation (glycation, N-glycosylation) process, characterized as a dynamic energy 
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for amino acid glycation. In their previous study, Labieniec-Watala and Watala demonstrated 
that in in vitro study that the parent PAMAM dendrimers (full-generation) have the ability to 
interact with molecules of glucose and make stable bonds. The non-enzymatic reaction amid the 
amine-end and glucose groups of dendrimers can undergo glycated/N-glycosylated dendrimers 
formation. Similarly, PAMAM dendrimers can serve as glucose hunter in hyperglycaemia, 
therefore resulted as reduced protein glycooxidation and glycation. The final N-glycosylated 
dendrimers of nonenzymatic N-glycosylation, neither result of fabricated and oriental chemical 
synthesis, their result became the potential applications source in several biomedicine branches 
[117].  
7.3. L-lysine modified PAMAM dendrimers  
The slightly modified amino terminal on surface of PAMAM acts as a good alternative in 
treating metabolic diabetes impairments. The modified, totally theoretical thought, seems 
believable to modify parent amino-terminal PAMAM to bind with lysine residues, result in 
“polylysylated” PAMAM dendrimers. These dendrimers attain 2 new liberated amine 
“valencies” of L-lysine (and g) for each one engaged primary amine group on the surface of the 
dendrimer, reasonably predictable that L-lysine modified PAMAM dendrimers become more 
effective in excessive glucose scavenging as compared to their non modified counter parts. When 
the non-enzymatic glycosylation process takes place accurately at the g amine groups of lysine 
residues on interactions with glucose, assumed that PAMAM dendrimer loaded with residues of 
lysine on dendrimer's surfaces may be an effective and ideal focus in diminishing the post 
enzymatic proteins modifications, and tentatively more suitable for scavenging than non-
lysylated dendrimers [117]. 
7.4. PEG modified PAMAM dendrimer 
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The cationic dendrimer modification using other molecules decreases the positive charge present 
on dendrimer's surface, and cause a gradual reduction in cytotoxicity. Therefore, the dendrimer's 
biological profile depending upon delivery systems differ from dendrimers with modified and 
unmodified surface [118]. Certainly, this has been established for complexes of DNA/PAMAM 
dendrimer [119] and oligonucleotide-dendrimer [116]. Between numerous methods yet to be 
researched, to overcome their significant limitation, the dendrimers modification via the 
attachment of PEG (polyethylene glycol) on dendrimers’ surface appears to be the most 
prominent [120]. There are unresolved questionnaire and facts of dendrimer systems intended for 
pharmaceutical applications due to their great water solubility, biological compatibility and 
capability to advance the biological carriers distribution [121]. Kim et al. demonstrated several 
examples to attach PEG on dendrimers surface by formation of different bonds, forming hybrids 
to different geometries, in which the drug delivery application is most prevailing [122]. Due to 
the polycationic PAMAM dendrimers toxicity, different approaches have been suggested to 
obscure the end amino groups. Between them, PAMAM's surfaces partial acetylation, in which 
the toxic fraction of amino groups was left unrevealed to accomplish attractive properties, deduct 
the hydrodynamic degree and affects the water solubility [123, 124].  
7.5. Lauroyl modified cationic PAMAM dendrimers 
Partial alteration of cationic PAMAM dendrimers to lauroyl terminal groups improved the 
permeability of membrane and reduced the cytotoxicity [118, 125]. The modification also 
enhances hydrophobicity, and support water aggregation by conjugated aliphatic chains. For 
example, modification using small alkyl alcohol groups points to reduce the cytotoxicity and also 
maintained the water solubility [124, 126]. Moreover, modification of PAMAM surface through 
moderately small functional groups needs complex regulation of stoichiometry for every 
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appended functional moiety to get both the pharmacological and physicochemical properties. A 
noticeable fall in the cationic PAMAM dendrimers cytotoxicity seemed, cells came in contact of 
lauroyl-PAMAM dendrimers. While concluded from estimated IC50 values, the cytotoxicity level 
of PAMAM G3 and G4 dendrimers conjugates by six lipid chains attached was >7-fold 
decreased as compared to unmodified dendrimers [127].  
7.6. Acetylated PAMAM dendrimers  
Acetylation of the reactive terminal groups of PAMAM dendrimers, route to particularly 
functionalize primary surface amines. When PAMAM dendrimers are acetylated, they become 
more water-soluble and the resulted quality is important for the biomedical applications which 
require more solubility in aqueous solvents [124, 127]. Though, systematic study of the science 
is not involved in PAMAMs acetylation that has been done. Majoros et al., conducted the 
primary study associated with PAMAM G5 acetylation, designed their protocol to research on 
the acetylation reaction's nature has been used, as well as to yield an investigation of well-
defined conjugates for dendrimer to use in the biomedical science field. Depending upon the data 
obtained by several techniques, like potentiometric titration, 
1
H NMR, 
13
C NMR and Gel 
permeation chromatography (GPC), the researchers concluded that the acetylated dendrimers 
unconditionally exhibited small molecular size in spite of their high molecular weight. 
Furthermore, they represented a highly compact design as compared to their non-acetylated 
analogues. However, the conversion of all primary amines into acetyl derivatives changes the 
dendrimer structure. The re-location of NMR characterized spectral peaks and appearance of 
some new peaks, concludes that modification of PAMAM G5 considered as a controlled and 
stoichiometric reaction (ratio of primary amine and acetic anhydride is 1:1). This information 
showed that stoichiometric property of the acetylation reaction, with an understanding of the 
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accurate amount of primary amine surface groups, confirmed a defined chemical structure for 
other dendrimer conjugates [126]. Kolhathar et al. studied two generations of PAMAM 
dendrimers (G2 and G4) and acetylated dendrimers and the result of surface advancement on 
permeability, uptake and cytotoxicity was determined through Caco-2 epithelial cells [128, 129]. 
These authors also showed that cationic PAMAM dendrimers can permeate across the Caco-2 
cells to a greater extent as their anionic or neutral counterparts [129]. The factors prompted the 
use of acetyl group for the surface functionalization are (1) an attractive interest in surface 
modification of dendrimers used for drug delivery, (2) simplicity of controlling the acetylation 
degree by regulating stoichiometry, (3) mild reaction environments requisite for acetylation, and 
(4) improved acetylated dendrimers solubility.  
The acetylated dendrimers shows less cytotoxicity and maintains good permeability. It is 
possible to make surface-modified PAMAM dendrimers specified for biomedical applications 
[128, 129]. Quintana et al used acetylation to reduce the non-definite binding linked with amino 
terminated nanoparticles [124]. Wiwattanapattapee et al. observed greater tissue uptake and 
reduced rate of serosal transfer for surface modified dendrimers as comparison to the non-
modified dendrimers [130]. PAMAM dendrimers consist of large number of tertiary amino 
groups inside, interacting with negative charged cell membranes and enhance the permeability. 
In animals PAMAM G4 (7-8 mg kg-1, c.a. 5.8 μM in circulating blood) was administered daily 
and revealed enhanced glycaemic control diabetes markers, though PAMAM-managed rats 
showed improved metabolic control of long term hyperglycaemia. Higher blood glucose level 
was established as protective counter to polycationic PAMAM-mediated increased mortality and 
cytotoxicity under chronic diabetes conditions [99].  
7.7. Arginine modified PAMAM dendrimer 
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In order to build up the transfection efficiency aimed for PAMAM dendrimers, different ligands 
were attached. A great deal of study has been done to introduce arginine in polymers like 
PAMAM dendrimers to enhance their transfection efficiency [131, 132]. Nam et al. confirmed 
that PAMAM dendrimers (G3 and G4) functionalized with lysine (PAMAM-K) or arginine 
(PAMAM-R) via an amide bound  showed a better transfection applications as compared to the  
plain G3 and G4 [133, 134]. Furthermore, researchers noticed that PAMAM dendrimers can be 
modified using arginine by biodegradable ester bond for two purposes. First, the attached 
arginine affects the formation of polyplex and penetrates the nucleus and cell membrane. 
Second, the polymers biodegradability affects the efficacy of intracellular disassembly for 
siRNAs and oligonucleotides as well as cell viability [135].  
7.8. Arginine modified PAMAM-OH dendrimer  
PAMAM-OH dendrimers having similar structure as PAMAM-NH2, excluding the surface-NH2 
groups of cationic dendrimers are exchanged for -OH groups. PAMAM-OH is non-toxic because 
of the lack of primary surface amines; however it barely forms DNA polyplexes due to a low 
pKa value of the internal tertiary amines. To manage this, biodegradable arginine (A)- and lysine 
(K)- conjugated constructed PAMAM dendrimers with ester bonds amid the surface -OH groups 
of PAMAM-OH and carboxylate groups of arginine and lysine (alluded as e-PAM-A and e-
PAM-K, respectively). Hence, it is concluded that PAMAM-OH dendrimers (especially arginine 
surface modified) have tremendous potential to become a safe and effective carrier of gene 
delivery with a high transfection efficiency, biodegradability, and low cytotoxicity [133]. Pisal et 
al., studied the permeability across the Caco-2 cell monolayers, and the cytotoxicity of PAMAM 
G4 dendrimers attached with ornithine and arginine. Their results showed that surface modified 
dendrimers were transported across the epithelial monolayers notably faster as compared to their 
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unmodified counterparts [135]. The result showed that PAMAM dendrimers simply modified at 
their surfaces by glycation, acetylation or acylation process; and these modifications make 
PAMAM dendrimers the least cytotoxic and more valuable for specific biomedical applications, 
e.g. gene or oral drug delivery [136]. When cationic polymers formed complexes, that shows less 
cytotoxicity in contrast to cationic free polymers [134]. 
8. CONCLUSION 
Dendrimers provides a strong platform for the delivery of drug molecules and bioactives. 
Dendrimers are monodisperse macromolecules with the presence of large number of surface 
groups which increases with the number of generation. The surface modification of dendrimers 
provides an opportunity for designing the carrier system with desired properties. Dendrimers can 
work as a useful tool for optimizing the drug delivery system. With the help of surface groups 
(including high density), a tunable toxicity profile of dendrimers as well as the targeting is 
possible. So, it is expected that in coming years, the researchers will achieve success to develop 
dendrimer based novel antidiabetic therapeutics which could be effective to control blood 
glucose level as well as complications associated with diabetes. 
Despite the broad endeavors and the advancement accomplished so far, the issues of a reliable 
technique for assessing nontoxic dosages of the tested PAMAM dendrimers are still 
undeveloped. Therefore, the main aim for future research ought to be the estimation of ideal 
dosages, at which dendrimers can be applied with the required effect. The quantity of 
laboratories directing in-vivo examinations with dendrimers is expanding gradually; the most 
appropriate (effective and non-toxic) method for administrations of dendrimers are still in need 
to be developed. Because of the ongoing endeavors for assessing the best technique for 
dendrimer DDS to organism, we consider the improvement and evaluating new methods of 
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dendrimer administration to be absolutely critical, featuring that the dendrimer route of delivery 
to targeted sites shows great impacts on the nature of treatment.  
A large portion of the results with respect to the activity and properties of dendrimers is taken 
from the results of in-vitro examinations. But, the results observed from the in-vitro and in-vivo 
examinations correspond poorly; subsequently, further examinations ought to be done so as to 
define and additionally exploit this tendency. Though, various reports appeared to be 
empowering and raise confidence for the potential utilization of dendrimers in an assortment of 
medicinal applications, their surprising expense of the fabrication and, subsequently, their high 
cost, may truly restrict the dendrimers use in the treatment of diabetes. 
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